Novo Nordisk has regained competitive ground in the obesity market with the strong launch of its Wegovy pill, which outperforms Eli Lilly's Foundayo in new prescriptions due to better weight loss results and fewer drug interaction limits. Despite recent setbacks, Novo Nordisk is advancing promising late-stage drug candidates aiming to compete with Eli Lilly's future products by the early 2030s. Both companies are expected to dominate obesity and diabetes markets through at least the mid-2030s, as no other competitors currently offer disruptive innovations in this space.
Novo Nordisk remains a Buy due to its strong long-term fundamentals and leadership in obesity treatment, particularly with its Wegovy pill. Although the company faces short-term issues like declining gross margins, high capital expenditures, and a fa...
Novo Nordisk has received a "Sell" rating due to growing competition from Eli Lilly and internal challenges like expiring patents and manufacturing issues. An analyst set a cautious price target of $47, reflecting concerns over flat to negative growt...
